Navigation Links
BioMed Realty Trust Promotes Kent Griffin to President

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on providing real estate to the life science industry, today announced that Kent Griffin has been promoted to President and Chief Operating Officer. Mr. Griffin will oversee the day-to-day operational activities and execution of the Company's business plan while continuing to serve as the Company's Chief Financial Officer.

Alan Gold, BioMed's Chief Executive Officer, remarked, "I am very pleased that the Board has chosen to recognize the contributions that Kent has made to BioMed, originating with him playing a key role in the Company's successful initial public offering in August 2004. As our Chief Financial Officer since 2006, Kent has been a critical member of our leadership team, developing and executing key financial strategies, while also taking an increasingly integral role in managing the growth of our organization and overseeing our operations."

Commenting on the promotion, Mr. Griffin said, "Alan and the BioMed team have built the premier real estate company for the life sciences industry with a portfolio of world-class life science research facilities. It is an honor and a privilege to be part of such a deep and talented team of real estate professionals committed to our mission -- creating value for our shareholders and opportunities for our employees by being the leading provider of real estate to the life science industry."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
2. BioFlorida Selects Collexis as the Primary Professional Network for its 200 Member Companies and Organizations
3. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
4. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
5. Ohio Becoming Global Hub for Biomedical Research and Commercialization
6. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
7. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
8. Global Med Technologies(R), Inc. Partners With Biomedical Synergies to Offer Advanced Tissue Tracking Solutions for Hospitals and Surgery Centers
9. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
10. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
11. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, will present at ... week in New York City . The ... December 1, 2015 at 9:30 a.m. EST. ... the website at least 15 minutes prior to the presentation ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
(Date:11/23/2015)... The royalty-free a greement a ... for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today announced ... agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral ... HCV virus.  The royalty-free licence will enable generic manufacture of ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):